Table 1 JIA disease characteristics and traditional cardiovascular risk factors
Variables | JIA patients (n = 81) | Controls (n = 41) |
|---|---|---|
Demographics | ||
Male gender; n (%) | 20 (25) | 9 (22) |
Age (years); median (IQR) | 38.6 (34.9–40.7) | 37.7 (34.8–40.5) |
Disease duration (years); median (IQR) | 29.3 (28.3–30.6) | |
Onset age (years); median (IQR) | 8.9 (4.9–11.8) | |
JIA subtype distribution | ||
Systemic arthritis; n (%) | 4 (5) | |
RF negative polyarthritis; n (%) | 11 (14) | |
RF positive polyarthritis; n (%) | 5 (6) | |
Persistent oligoarthritis; n (%) | 14 (17) | |
Extended oligoarthritis; n (%) | 13 (16) | |
Entesitis related arthritis; n (%) | 18 (22) | |
Psoriatic arthritis; n (%) | 14 (17) | |
Unclassified arthritis; n (%) | 2 (3) | |
Current medication at 29-year follow-up | ||
Anti-TNF; n (%) | 25 (31) | |
Metotrexat; n (%) | 19 (24) | |
NSAIDs daily; n (%) | 23 (28) | |
Prednisolone; n (%) | 5 (6.2) | |
Cardiovascular risk factors | ||
BMI (kg/m2); mean (SD) | 25.7 (5.0) | 25.3 (3.9) |
Waist circumference (cm); mean (SD) | 92.7 (12.7) | 92.7 (9.0) |
Daily smokers; n (%) | 18 (22) | 5 (12) |
CVD in first degree relative; n (%) | 46 (57) | 19 (46) |
Hypertension; n (%) | 9 (11) | 0 (0)* |
Myocardial infarction; n (%) | 1 (1) | 0 (0) |
Total cholesterol (mmol/L); mean (SD) | 4.9 (1.1) | 4.9 (0.8) |
LDL cholesterol (mmol/L); mean (SD) | 3.0 (1.0) | 3.0 (0.8) |
hs-CRP (mg/L); median (IQR) | 1.8 (0.7–5.0) | 0.7 (0.0–1.9)* |
Insulin resistance | 1.1 (1.1) | 0.9 (0.6) |